BACKGROUND: Cigarette smoking has been shown to increase the risk of developing colorectal cancer, particularly smoking early in life. Little is known about the impact of tobacco use on colon cancer recurrence among colon cancer survivors. METHODS: The authors prospectively collected lifetime smoking history from stage III colon cancer patients enrolled in a phase 3 trial via self-report questionnaires during and 6 months after completion of adjuvant chemotherapy. Smoking status was defined as never, current, or past. Lifetime pack-years were defined as number of lifetime packs of cigarettes. Patients were followed for recurrence or death. RESULTS: Data on smoking history were captured on 1045 patients with stage III colon cancer receivingadjuvant therapy (46% never smokers; 44% past; 10% current). The adjusted hazard ratio (HR) for disease-free survival (DFS) was 0.99 (95% confidence interval [CI], 0.70-1.41), 1.17 (95% CI 0.89-1.55), and 1.22 (95% CI 0.92-1.61) for lifetime pack-years 0-10, 10-20, and 20+, respectively, compared with never smoking (P = .16). In a preplanned exploratory analysis of smoking intensity early in life, the adjusted HR for 12+ pack-years before age 30 years for DFS was 1.37 (95% CI, 1.02-1.84) compared with never smoking (P = .04). The adjusted HR for DFS was 1.18 (95% CI, 0.92-1.50) for past smokers and 1.10 (95% CI, 0.73-1.64) for current smokers, compared with never smokers. CONCLUSIONS: Total tobacco usage early in life may be an important, independent prognostic factor of cancer recurrences and mortality in patients with stage III colon cancer.
RCT Entities:
BACKGROUND: Cigarette smoking has been shown to increase the risk of developing colorectal cancer, particularly smoking early in life. Little is known about the impact of tobacco use on colon cancer recurrence among colon cancer survivors. METHODS: The authors prospectively collected lifetime smoking history from stage III colon cancerpatients enrolled in a phase 3 trial via self-report questionnaires during and 6 months after completion of adjuvant chemotherapy. Smoking status was defined as never, current, or past. Lifetime pack-years were defined as number of lifetime packs of cigarettes. Patients were followed for recurrence or death. RESULTS: Data on smoking history were captured on 1045 patients with stage III colon cancer receiving adjuvant therapy (46% never smokers; 44% past; 10% current). The adjusted hazard ratio (HR) for disease-free survival (DFS) was 0.99 (95% confidence interval [CI], 0.70-1.41), 1.17 (95% CI 0.89-1.55), and 1.22 (95% CI 0.92-1.61) for lifetime pack-years 0-10, 10-20, and 20+, respectively, compared with never smoking (P = .16). In a preplanned exploratory analysis of smoking intensity early in life, the adjusted HR for 12+ pack-years before age 30 years for DFS was 1.37 (95% CI, 1.02-1.84) compared with never smoking (P = .04). The adjusted HR for DFS was 1.18 (95% CI, 0.92-1.50) for past smokers and 1.10 (95% CI, 0.73-1.64) for current smokers, compared with never smokers. CONCLUSIONS: Total tobacco usage early in life may be an important, independent prognostic factor of cancer recurrences and mortality in patients with stage III colon cancer.
Authors: Brenda Diergaarde; Alina Vrieling; Annemieke A van Kraats; Goos N P van Muijen; Frans J Kok; Ellen Kampman Journal: Carcinogenesis Date: 2003-03 Impact factor: 4.944
Authors: M L Slattery; K Curtin; K Anderson; K N Ma; L Ballard; S Edwards; D Schaffer; J Potter; M Leppert; W S Samowitz Journal: J Natl Cancer Inst Date: 2000-11-15 Impact factor: 13.506
Authors: K M Smits; L Gaspari; M P Weijenberg; V Dolzan; K Golka; H C Roemer; V Nedelcheva Kristensen; M C Lechner; G I Mehling; J Seidegard; R C Strange; E Taioli Journal: Biomarkers Date: 2003 May-Aug Impact factor: 2.658
Authors: E Giovannucci; G A Colditz; M J Stampfer; D Hunter; B A Rosner; W C Willett; F E Speizer Journal: J Natl Cancer Inst Date: 1994-02-02 Impact factor: 13.506
Authors: E Giovannucci; E B Rimm; M J Stampfer; G A Colditz; A Ascherio; J Kearney; W C Willett Journal: J Natl Cancer Inst Date: 1994-02-02 Impact factor: 13.506
Authors: Gregory J Tranah; Edward Giovannucci; Jing Ma; Charles Fuchs; Susan E Hankinson; David J Hunter Journal: Carcinogenesis Date: 2004-02-26 Impact factor: 4.944
Authors: Glen Morgan; Robert A Schnoll; Catherine M Alfano; Sarah E Evans; Adam Goldstein; Jamie Ostroff; Elyse Richelle Park; Linda Sarna; Lisa Sanderson Cox Journal: J Oncol Pract Date: 2011-05 Impact factor: 3.840
Authors: Amanda I Phipps; Qian Shi; Polly A Newcomb; Garth D Nelson; Daniel J Sargent; Steven R Alberts; Paul J Limburg Journal: J Clin Oncol Date: 2013-04-01 Impact factor: 44.544
Authors: Sandra J Japuntich; Pallavi Kumar; Jane F Pendergast; Grelda Yazmin Juarez Caballero; Jennifer L Malin; Robert B Wallace; Elizabeth A Chrischilles; Nancy L Keating; Elyse R Park Journal: Nicotine Tob Res Date: 2019-03-30 Impact factor: 4.244
Authors: Colleen Pelser; Hannah Arem; Ruth M Pfeiffer; Joanne W Elena; Catherine M Alfano; Albert R Hollenbeck; Yikyung Park Journal: Cancer Date: 2014-03-03 Impact factor: 6.860
Authors: J M Ordóñez-Mena; V Walter; B Schöttker; M Jenab; M G O'Doherty; F Kee; B Bueno-de-Mesquita; P H M Peeters; B H Stricker; R Ruiter; A Hofman; S Söderberg; P Jousilahti; K Kuulasmaa; N D Freedman; T Wilsgaard; A Wolk; L M Nilsson; A Tjønneland; J R Quirós; F J B van Duijnhoven; P D Siersema; P Boffetta; A Trichopoulou; H Brenner Journal: Ann Oncol Date: 2018-02-01 Impact factor: 32.976